{"protocolSection":{"identificationModule":{"nctId":"NCT03600376","orgStudyIdInfo":{"id":"EGL-4104-C-1801"},"organization":{"fullName":"Eagle Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS","officialTitle":"Phase 3, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)"},"statusModule":{"statusVerifiedDate":"2021-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-08-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-08-14","type":"ACTUAL"},"completionDateStruct":{"date":"2019-08-14","type":"ACTUAL"},"studyFirstSubmitDate":"2018-07-17","studyFirstSubmitQcDate":"2018-07-17","studyFirstPostDateStruct":{"date":"2018-07-26","type":"ACTUAL"},"resultsFirstSubmitDate":"2021-03-29","resultsFirstSubmitQcDate":"2021-03-29","resultsFirstPostDateStruct":{"date":"2021-04-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-04-28","lastUpdatePostDateStruct":{"date":"2021-05-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eagle Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A double-blind, parallel study of Ryanodex for the adjuvant treatment of exertional heat stroke (EHS) compared to current Standard of Care (SOC) for EHS.","detailedDescription":"Following triage and primary assessment in the emergency medical facility, subjects will be randomized to 1 of 2 treatment arms, SOC plus Ryanodex or SOC only. Subjects will be dosed and followed for up to 6 hours post-randomization. Current SOC is limited to body cooling and supportive measures."},"conditionsModule":{"conditions":["Exertional Heat Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Ryanodex (dantrolene sodium) for injectable suspension plus Standard of Care","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","CARE_PROVIDER"]}},"enrollmentInfo":{"count":17,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Ryanodex and Standard of Care","type":"EXPERIMENTAL","description":"In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.","interventionNames":["Drug: Ryanodex and Standard of Care"]},{"label":"Standard of Care only (SOC)","type":"OTHER","description":"Standard of Care treatment will consist of the immediate start of cooling measures.","interventionNames":["Other: Standard of Care"]}],"interventions":[{"type":"DRUG","name":"Ryanodex and Standard of Care","description":"Ryanodex to be administered as a rapid IV push","armGroupLabels":["Ryanodex and Standard of Care"],"otherNames":["Ryanodex and SOC"]},{"type":"OTHER","name":"Standard of Care","description":"Body cooling measures and supportive measures","armGroupLabels":["Standard of Care only (SOC)"],"otherNames":["SOC"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS â‰¥ 13 [Time Frame: 90 Minutes Post-randomization]","description":"The GCS is a validated and reliable scale to evaluate level of consciousness in patients with acute brain injury. The scale assesses 3 functions: Eye Opening, Verbal Response, and Motor Response. GCS scores range from 15 (best) to 3 (worst).","timeFrame":"90 minutes post-randomization"}],"secondaryOutcomes":[{"measure":"Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]","description":"The GCS is a validated and reliable scale to evaluate level of consciousness in patients with acute brain injury. The scale assesses 3 functions: Eye Opening, Verbal Response, and Motor Response. GCS scores range from 15 (best) to 3 (worst).","timeFrame":"Treatment duration, up to 6 hours"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria: Core body temperature of greater than or equal to 40.0 degrees C (104 degrees F); recent history of exertional activity; GCS score less than 13; tachycardia -\n\nExclusion Criteria: clinical severe infection; hyperthermia secondary to another condition; endotracheal intubation;; sedative drugs administered prior to or at time of study entry; likelihood of head trauma within 6 months pre-study; positive pregnancy test; history of myocardial infection within 30 days; history of seizure disorder or epilepsy; concomitant or prior use of calcium channel blockers.\n\n-","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Adrian Hepner","affiliation":"Eagle Pharmaceuticals, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"King Faisal Hospital","city":"Mecca","country":"Saudi Arabia","geoPoint":{"lat":21.42664,"lon":39.82563}},{"facility":"Mina al Jisr Hospital","city":"Mina","country":"Saudi Arabia","geoPoint":{"lat":21.41333,"lon":39.89472}},{"facility":"Mina Al-Shari Al-Jadeed Hospital","city":"Mina","country":"Saudi Arabia","geoPoint":{"lat":21.41333,"lon":39.89472}},{"facility":"Mina Al-Wadi Hospital","city":"Mina","country":"Saudi Arabia","geoPoint":{"lat":21.41333,"lon":39.89472}}]},"referencesModule":{"references":[{"pmid":"33848093","type":"DERIVED","citation":"Fisher JD, Shah AP, Norozian F. Clinical Spectrum of Pediatric Heat Illness and Heatstroke in a North American Desert Climate. Pediatr Emerg Care. 2022 Feb 1;38(2):e891-e893. doi: 10.1097/PEC.0000000000002438."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Ryanodex and Standard of Care","description":"In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.\n\nRyanodex and Standard of Care: Ryanodex to be administered as a rapid IV push"},{"id":"FG001","title":"Standard of Care Only (SOC)","description":"Standard of Care treatment will consist of the immediate start of cooling measures.\n\nStandard of Care: Body cooling measures and supportive measures"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"6"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Transferred to other facility","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Investigator Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Determined to be ineligible for study","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Ryanodex and Standard of Care","description":"In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.\n\nRyanodex and Standard of Care: Ryanodex to be administered as a rapid IV push"},{"id":"BG001","title":"Standard of Care Only (SOC)","description":"Standard of Care treatment will consist of the immediate start of cooling measures.\n\nStandard of Care: Body cooling measures and supportive measures"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"55.3","spread":"7.2"},{"groupId":"BG001","value":"53.4","spread":"11.2"},{"groupId":"BG002","value":"54.4","spread":"9.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"}]}],"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"14"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"}]}],"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"10"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Saudi Arabia","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"86.1","spread":"16.9"},{"groupId":"BG001","value":"84.2","spread":"12.9"},{"groupId":"BG002","value":"85.2","spread":"14.7"}]}]}]},{"title":"Height","populationDescription":"It was not possible to obtain accurate height measurements for several patients due to the extreme nature of their medical condition.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"cm","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"14"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"162.8","spread":"7.6"},{"groupId":"BG001","value":"159.3","spread":"7.7"},{"groupId":"BG002","value":"161.3","spread":"7.6"}]}]}]},{"title":"BMI","populationDescription":"It was not possible to calculate BMI for several patients due to the extreme nature of their medical condition.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"14"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"32.4","spread":"5.9"},{"groupId":"BG001","value":"33.2","spread":"5.7"},{"groupId":"BG002","value":"32.7","spread":"5.6"}]}]}]},{"title":"Glasgow Coma Scale Score","description":"The Glasgow Coma Scale (GCS) is a reliable and objective way of recording the initial and subsequent level of consciousness in a person after a brain injury. Higher total GCS represents a better outcome. The scores of subscales are summed to determine the total score.\n\nThe range of total GCS score is from 3 - 15 where 13-15 is Mild; 9 - 12 is Moderate; and 3 -8 is Severe.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"5.6","spread":"2.7"},{"groupId":"BG001","value":"5.5","spread":"2.7"},{"groupId":"BG002","value":"5.5","spread":"2.6"}]}]}]},{"title":"Rectal Temperature","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Degrees Celsius","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"41.8","spread":"1.2"},{"groupId":"BG001","value":"41.3","spread":"0.9"},{"groupId":"BG002","value":"41.5","spread":"1.1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS â‰¥ 13 [Time Frame: 90 Minutes Post-randomization]","description":"The GCS is a validated and reliable scale to evaluate level of consciousness in patients with acute brain injury. The scale assesses 3 functions: Eye Opening, Verbal Response, and Motor Response. GCS scores range from 15 (best) to 3 (worst).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"90 minutes post-randomization","groups":[{"id":"OG000","title":"Ryanodex and Standard of Care","description":"In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.\n\nRyanodex and Standard of Care: Ryanodex to be administered as a rapid IV push"},{"id":"OG001","title":"Standard of Care Only (SOC)","description":"Standard of Care treatment will consist of the immediate start of cooling measures.\n\nStandard of Care: Body cooling measures and supportive measures"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]","description":"The GCS is a validated and reliable scale to evaluate level of consciousness in patients with acute brain injury. The scale assesses 3 functions: Eye Opening, Verbal Response, and Motor Response. GCS scores range from 15 (best) to 3 (worst).","populationDescription":"the outcome measure data table below is a summary of results showing the cumulative proportion of subjects achieving GCS score â‰¥13 post-randomization at all planned time points. Data is cumulative therefore the counts in the categories below will not add up to the Number Analyzed.\n\nscore â‰¥ 13 post-randomization at all planned time points in the study is shown","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Treatment duration, up to 6 hours","groups":[{"id":"OG000","title":"Ryanodex and Standard of Care","description":"In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.\n\nRyanodex and Standard of Care: Ryanodex to be administered as a rapid IV push"},{"id":"OG001","title":"Standard of Care Only (SOC)","description":"Standard of Care treatment will consist of the immediate start of cooling measures.\n\nStandard of Care: Body cooling measures and supportive measures"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"classes":[{"title":"Pts. achieving GCS score â‰¥ 13 at 15 min post-randomization","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Pts. achieving GCS score â‰¥ 13 at 30 min. post-randomization","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Pts. achieving GCS score â‰¥ 13 after 45 min. post-randomization","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Pts. achieving GCS score â‰¥ 13 after 60 min. post-randomization","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Pts. achieving GCS score â‰¥ 13 after 75 min. post-randomization","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Pts. achieving GCS score â‰¥ 13 after 90 min. post-randomization","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]},{"title":"Pts. achieving GCS score â‰¥ to 13 after 2 hr.. post-randomization","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"Pts. achieving GCS score â‰¥ 13 after 4 hr. post-randomization/follow-up phase","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"Pts. achieving GCS score â‰¥ 13 at end of study or early termination","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"Adverse events data was collected from time of randomization through end of study (6 hours post-randomization) or early termination.","eventGroups":[{"id":"EG000","title":"Ryanodex and Standard of Care","description":"In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.\n\nRyanodex and Standard of Care: Ryanodex to be administered as a rapid IV push","deathsNumAffected":0,"deathsNumAtRisk":9,"seriousNumAffected":1,"seriousNumAtRisk":9,"otherNumAffected":7,"otherNumAtRisk":9},{"id":"EG001","title":"Standard of Care Only (SOC)","description":"Standard of Care treatment will consist of the immediate start of cooling measures.\n\nStandard of Care: Body cooling measures and supportive measures","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":2,"seriousNumAtRisk":8,"otherNumAffected":5,"otherNumAtRisk":8}],"seriousEvents":[{"term":"Coma Scale Abnormal","organSystem":"Investigations","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8}]}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Coma Scale Abnormal","organSystem":"Investigations","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":8}]},{"term":"Agitation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDra Version 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The PIs are not permitted to discuss or publish study results."},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eagle Pharmaceuticals, Inc.","email":"medinfo@eagleus.com","phone":"201-326-5300"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2020-01-03","uploadDate":"2021-03-29T08:38","filename":"Prot_000.pdf","size":946475},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-01-03","uploadDate":"2021-03-29T08:39","filename":"SAP_001.pdf","size":501109}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000018883","term":"Heat Stroke"},{"id":"D000013474","term":"Sunstroke"}],"ancestors":[{"id":"D000018882","term":"Heat Stress Disorders"},{"id":"D000014947","term":"Wounds and Injuries"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M20615","name":"Heat Stroke","asFound":"Heat Stroke","relevance":"HIGH"},{"id":"M15946","name":"Sunstroke","asFound":"Heat Stroke","relevance":"HIGH"},{"id":"M24606","name":"Stress Disorders, Traumatic","relevance":"LOW"},{"id":"M20614","name":"Heat Stress Disorders","relevance":"LOW"},{"id":"M17375","name":"Wounds and Injuries","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC26","name":"Wounds and Injuries"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000003620","term":"Dantrolene"}],"ancestors":[{"id":"D000009125","term":"Muscle Relaxants, Central"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M6512","name":"Dantrolene","asFound":"Alanyl-Glutamine","relevance":"HIGH"}],"browseBranches":[{"abbrev":"MuRelCen","name":"Muscle Relaxants, Central"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}